A drug that has carried one of the highest sticker prices in the American pharmacy is about to cost Medicare far less. Beginning in 2027, the program’s negotiated price for the semaglutide family sold as Ozempic and Wegovy falls to $274 a month, down from a list price near $959. The reduction is one of the largest in the newest round of federal drug-price negotiations, and it reshapes what taxpayers spend on a class of medicines that has driven up program costs quickly.
What the $274 figure actually represents
The new number is the price Medicare will pay under its negotiation authority, not an automatic out-of-pocket cost for the person filling the prescription. What a Medicare beneficiary pays at the counter still runs through a specific Part D plan and depends on that plan’s deductible, cost-sharing tier, and coverage phase.
Even so, the negotiated price sets the baseline the whole system prices from, and a drop from roughly $959 to $274 is a reduction of about 71 percent, as detailed in reporting on the 2027 negotiated prices. Lower program spending on a high-volume drug generally flows through to plan design and, over time, to what enrollees pay.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
Why semaglutide landed on the negotiation list
The price was set under the drug-negotiation provisions of the Inflation Reduction Act, which let Medicare bargain directly over a growing list of the medicines it spends the most on. Semaglutide qualified because of both its cost per prescription and its rapid uptake among older adults managing diabetes and, in the Wegovy formulation, weight-related conditions.
The negotiated price takes effect January 1, 2027, alongside reduced prices for more than a dozen other drugs. Federal estimates tied to the round point to billions in annual savings for the program once the new prices apply.
The negotiation process itself is deliberate and evidence-based. The government identifies high-spend drugs that lack meaningful competition, then bargains toward a maximum fair price using clinical value and existing market prices as reference points. Semaglutide’s combination of a steep list price and heavy use among older adults made it a natural target the first time it became eligible. The size of the resulting cut, roughly 71 percent off the list figure, reflects how far the negotiated price sits below what the program had been paying, and it ranks among the largest reductions in the current batch of negotiated medicines.
Where the savings do and do not reach
The negotiated price applies only to people covered by Medicare. It does not change what a commercial insurer, a Medicaid program, or a cash-paying customer is charged for the same medicine. For a retiree on a Part D plan, the practical effect shows up in how the plan calculates cost-sharing once the lower price is in force, and in how quickly spending moves through the annual out-of-pocket cap that now limits total drug costs.
That cap is the other half of the picture. A lower per-prescription price means a beneficiary reaches the spending ceiling more slowly, which can hold down the running total across a year of refills even when a single month’s copay looks unchanged.
There is also a behavioral dimension the price change touches. Studies of high-cost medicines consistently find that some patients skip doses or abandon prescriptions entirely when the price climbs too high, undermining the treatment the drug was meant to provide. A negotiated price that pulls the program’s cost down toward $274 removes part of the pressure that had pushed the sticker figure near $959, which matters for a class of drugs where consistent use is the point. Whether that translates into steadier adherence depends on how individual plans set their 2027 cost-sharing, but the direction of the change reduces one barrier that had kept some retirees from filling the prescription at all.
The cost angle for older households
For households on fixed incomes, a medicine priced near $959 was a budget line that could crowd out everything else, and many simply went without or rationed doses. A negotiated Medicare price of $274 changes the math the program works from, and general Medicare cost rules published by Medicare govern how that price then translates into plan-level charges. The gap between the headline price and the counter price is exactly why the distinction matters: the negotiated figure is a program cost, and the personal cost still depends on plan choice at enrollment.
What to watch before January
The negotiated price is settled, but each Part D plan will publish its own 2027 formulary and cost-sharing terms during the fall enrollment season, and that is where the $274 figure becomes a real-world copay. The plans that place semaglutide on a favorable tier will pass more of the reduction through than those that do not, so the comparison among plans is where the savings are captured or lost. The negotiation set the floor; the plan filings decide how much of it reaches the pharmacy counter.
This article was produced with the assistance of artificial intelligence and reviewed by The Financial Wire editorial team.
More Financial Reading
- How many CDs can you park at 1 bank? FDIC rules you must know
- The ideal retirement withdrawal rate so your savings actually last
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
